TY - JOUR
T1 - Diagnosis and treatment of bone metastasis
T2 - Comprehensive guideline of the Japanese Society of Medical Oncology, Japanese Orthopedic Association, Japanese Urological Association, and Japanese Society for Radiation Oncology
AU - Shibata, H.
AU - Kato, S.
AU - Sekine, I.
AU - Abe, K.
AU - Araki, N.
AU - Iguchi, H.
AU - Izumi, T.
AU - Inaba, Y.
AU - Osaka, I.
AU - Kato, S.
AU - Kawai, A.
AU - Kinuya, S.
AU - Kodaira, M.
AU - Kobayashi, E.
AU - Kobayashi, T.
AU - Sato, J.
AU - Shinohara, N.
AU - Takahashi, S.
AU - Takamatsu, Y.
AU - Takayama, K.
AU - Takayama, K.
AU - Tateishi, U.
AU - Nagakura, H.
AU - Hosaka, M.
AU - Morioka, H.
AU - Moriya, T.
AU - Yuasa, T.
AU - Yurikusa, T.
AU - Yomiya, K.
AU - Yoshida, M.
N1 - Funding Information:
1Department of Clinical Oncology, Akita University Graduate School of Medicine, Akita, Japan 2Department of Clinical Oncology, Juntendo University, Tokyo, Japan 3Department of Clinical Oncology, University of Tsukuba, Tsukuba, Japan 4Department of Rehabilitation, Chiba Prefectural University of Health Sciences, Chiba, Japan 5Department of Orthopedic Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan 6Department of Gastroenterology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan 7Division of Hematology, Tochigi Cancer Center, Utsunomiya, Japan 8Department of Diagnostic and Interventional Radiology, Aichi Cancer Center Hospital, Nagoya, Japan 9Division of Palliative Medicine, Shizuoka Cancer Center, Sunto-gun, Japan 10Department for Cancer Chemotherapy, Iwate Prefectural Central Hospital, Morioka, Japan 11Division of Musculoskeletal Oncology, National Cancer Center Hospital, Tokyo, Japan 12Department of Nuclear Medicine, Kanazawa University Hospital, Kanazawa, Japan 13Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan 14Department of Diagnostic and Interventional Radiology, Ishikawa Prefectural Central Hospital, Kanazawa, Japan
Funding Information:
Competing interests S Kato, sponsored research (Chugai Pharmaceutical Co, Ltd); IO, honoraria (Taiho Pharmaceutical Co, Ltd); S Kinuya, data and safety monitoring board (Bayer Yakuhin, Ltd); NS, honoraria (Novartis Pharma); ST, honoraria (Astellas Pharma Inc, AstraZeneca plc, Daiichi Sankyo Co, Ltd, Novartis Pharma), sponsored research (Sanofi, Zenyaku Kogyo Co, Ltd, Taiho Pharmaceutical Co, Ltd, Boehringer Ingelheim Japan, Chugai Pharmaceutical Co, Ltd, Novartis Pharma); YT, honoraria (Janssen Pharma); K Takayama20, consultation and honoraria (Clinical Research Support Center Kyushu, AstraZeneca plc, Chugai Pharmaceutical Co, Ltd, Eli Lilly Japan, PfizerJapan Inc), sponsored research (Kyowa Hakko Kirin Co, Ltd, plc, Daiichi Sankyo Co, Ltd, Chugai Pharmaceutical Co, Ltd, Eli Lilly Japan, Novartis Pharma, Bristol-Myers Squibb); UT, consultation and honoraria (Micron Inc, SymBio Pharmaceutical Co, Ltd, Chugai Pharmaceutical Co, Ltd, Nihon Medi-Physics Co, Ltd); HM, sponsored research (Eisai Co, Ltd, Taiho Pharmaceutical Co, Ltd); T Yuasa, honoraria (Novartis Pharma, PfizerJapan Inc).
Funding Information:
15Department of Clinical Pharmaceutics, School of Pharmacy, Iwate Medical University, Morioka, Japan 16Department of Renal and Genitourinary Surgery, Hokkaido University Graduate School of Medicine, Sapporo, Japan 17Department of Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan 18Division of Medical Oncology, Hematology and Infectious Diseases, Fukuoka University Hospital, Fukuoka, Japan 19Seirei Christopher University, Hamamatsu, Japan 20Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan 21Department of Diagnostic Radiology and Nuclear Medicine, Tokyo Medical and Dental University, Tokyo, Japan 22Department of Radiology, KKR Sapporo Medical Center, Sapporo, Japan 23Department of Orthopaedic Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan 24Department of Orthopaedic Surgery, Keio University School of Medicine, Tokyo, Japan 25Department of Pathology 2, Kawasaki Medical School, Kurashiki, Japan 26Department of Urology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan 27Division of Dentistry and Oral Surgery, Shizuoka Cancer Center, Sunto-gun, Japan 28Department of Palliative Care, Saitama Cancer Center, Kitaadachi-gun, Japan 29Department of Hemodialysis and Surgery, Chemotherapy Research Institute, International University of Health and Welfare, Ichikawa, Japan
Publisher Copyright:
© Published by the BMJ Publishing Group Limited.
PY - 2016/3
Y1 - 2016/3
N2 - Diagnosis and treatment of bone metastasis requires various types of measures, specialists and caregivers. To provide better diagnosis and treatment, a multidisciplinary team approach is required. The members of this multidisciplinary team include doctors of primary cancers, radiologists, pathologists, orthopaedists, radiotherapists, clinical oncologists, palliative caregivers, rehabilitation doctors, dentists, nurses, pharmacists, physical therapists, occupational therapists, medical social workers, etc. Medical evidence was extracted from published articles describing meta-analyses or randomised controlled trials concerning patients with bone metastases mainly from 2003 to 2013, and a guideline was developed according to the Medical Information Network Distribution Service Handbook for Clinical Practice Guideline Development 2014. Multidisciplinary team meetings are helpful in diagnosis and treatment. Clinical benefits such as physical or psychological palliation obtained using the multidisciplinary team approaches are apparent. We established a guideline describing each specialty field, to improve understanding of the different fields among the specialists, who can further provide appropriate treatment, and to improve patients' outcomes.
AB - Diagnosis and treatment of bone metastasis requires various types of measures, specialists and caregivers. To provide better diagnosis and treatment, a multidisciplinary team approach is required. The members of this multidisciplinary team include doctors of primary cancers, radiologists, pathologists, orthopaedists, radiotherapists, clinical oncologists, palliative caregivers, rehabilitation doctors, dentists, nurses, pharmacists, physical therapists, occupational therapists, medical social workers, etc. Medical evidence was extracted from published articles describing meta-analyses or randomised controlled trials concerning patients with bone metastases mainly from 2003 to 2013, and a guideline was developed according to the Medical Information Network Distribution Service Handbook for Clinical Practice Guideline Development 2014. Multidisciplinary team meetings are helpful in diagnosis and treatment. Clinical benefits such as physical or psychological palliation obtained using the multidisciplinary team approaches are apparent. We established a guideline describing each specialty field, to improve understanding of the different fields among the specialists, who can further provide appropriate treatment, and to improve patients' outcomes.
KW - a diagnosis and treatment guideline
KW - bone metastasis
KW - multidisciplinary team approach
UR - http://www.scopus.com/inward/record.url?scp=85049714044&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85049714044&partnerID=8YFLogxK
U2 - 10.1136/esmoopen-2016-000037
DO - 10.1136/esmoopen-2016-000037
M3 - Review article
AN - SCOPUS:85049714044
VL - 1
JO - ESMO Open
JF - ESMO Open
SN - 2059-7029
IS - 2
M1 - e000037
ER -